In addition, Bissler and colleagues investigated another mTOR inhibitor, sirolimus, treatment for RAML in patients with tuberous sclerosis or sporadic LAM and found a mean reduction in RAML volume of 47% at 12 months [18]. This evidence concerns the gene MTOR and lymphangioleiomyomatosis.